Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 4/20 | 0.38 |
| ▸ | BRD4 | O60885 | 9/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2965356 | 0.90 | ACVR1 (0.38) | ACVR1BRD4TGFBR1KDRMAPK14 | |
| SCHEMBL2962772 | 0.86 | BRAF (0.42) | ACVR1BRD4 | |
| SCHEMBL20573409 | 0.78 | CYP2C19 (0.38) | ACVR1TGFBR1CYP2C19JAK3 | |
| SCHEMBL13199869 | 0.78 | CYP2C19 (0.38) | CYP2C19JAK3 | |
| SCHEMBL2968816 | 0.76 | BRAF (0.37) | BRD4TGFBR1KDRMAPK14RIPK2 | |
| SCHEMBL20573357 | 0.71 | CYP2C19 (0.30) | CYP2C19 | |
| SCHEMBL2955874 | 0.68 | ACVR1 (0.41) | ACVR1KDRMAPK14JAK2JAK1 | |
| SCHEMBL13199868 | 0.68 | CYP2C19 (0.38) | TGFBR1MAPK14CYP2C19 | |
| SCHEMBL2960526 | 0.66 | CYP2C19 (0.43) | MAPK14CYP2C19 | |
| SCHEMBL2963637 | 0.65 | BRAF (0.45) | ACVR1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | ACVR1 4191/4885BRD4 569/4885TGFBR1 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.